drugset / Trial / NCT05793450
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
Timeline
- Start
- 2023-05-05
- Primary completion
- 2023-09-18
- Completion
- 2023-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mazdutide | Protein / enzyme biologic | 2 mg | Subcutaneous |